Avoro Capital Advisors LLC Mirati Therapeutics, Inc. Transaction History

Avoro Capital Advisors LLC

$8.3 Billion
Q1 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$41.99 - $62.38 $74.7 Million - $111 Million	-1,779,826 Reduced 26.7%	4,886,840 $287 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $30.9 Million - $50.4 Million	1,111,111 Added 20.0%	6,666,666 $290 Million
Q4 2022 Feb 14, 2023	BUY	$41.27 - $98.62 $206,350 - $493,100	5,000 Added 0.09%	5,555,555 $252 Million
Q2 2022 Aug 15, 2022	BUY	$39.16 - $88.71 $8.83 Million - $20 Million	225,555 Added 4.24%	5,550,555 $373 Million
Q1 2022 May 16, 2022	BUY	$75.82 - $150.97 $19 Million - $37.7 Million	250,000 Added 4.93%	5,325,000 $438 Million

Q4 2021 Feb 14, 2022	BUY	$132.01 - $190.29 $9.9 Million - $14.3 Million	75,000 Added 1.5%	5,075,000 $744 Million
Q2 2021 Aug 16, 2021	BUY	$144.0 - $179.73 $46.8 Million - $58.4 Million	325,000 Added 6.95%	5,000,000 $808 Million
Q1 2021 May 17, 2021	BUY	$158.92 - $221.61 $22.2 Million - $31 Million	140,000 Added 3.09%	4,675,000 $801 Million
Q4 2020 Feb 16, 2021	BUY	$162.05 - $240.27 $31.1 Million - $46.1 Million	192,000 Added 4.42%	4,535,000 $996 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $6.37 Million - $9.41 Million	56,235 Added 1.31%	4,343,000 $721 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $12.5 Million - $21 Million	174,065 Added 4.23%	4,286,765 $489 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $18.3 Million - $30.5 Million	262,500 Added 6.82%	4,112,700 $316 Million
Q4 2019 Feb 14, 2020	BUY	$70.76 - $128.86 $7.09 Million - $12.9 Million	100,200 Added 2.67%	3,850,200 $496 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $8.76 Million - $12.3 Million	-112,500 Reduced 2.91%	3,750,000 $292 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $40.8 Million - $73.9 Million	-935,601 Reduced 19.5%	3,862,500 $283 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $10.4 Million - $21 Million	400,000 Added 9.09%	4,798,101 $237 Million
Q4 2017 Feb 14, 2018	BUY	$12.65 - $19.0 $8.7 Million - $13.1 Million	687,500 Added 18.53%	4,398,101 $80.3 Million
Q3 2017 Nov 14, 2017	BUY	$4.7 - $11.7 $17.4 Million - $43.4 Million	3,710,601	3,710,601 $43.4 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Avoro Capital Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Avoro Capital Advisors LLC with notifications on news.

Account